Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
This article was originally published in PharmAsia News
Executive Summary
Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28